Extension of Research Term. The Parties may mutually agree in writing to further extend the Research Program for one (1) or more additional years on terms and conditions to be mutually agreed.
Extension of Research Term. [*] ([*]) days prior to the expiration of the initial Research Term, the JRC shall discuss the possibility of extending the Research Program and correspondingly the Research Term. In such event, if the Parties do not reach agreement on an extension of the Research Term prior to the expiration of the initial Research Term, then the expiration date for the initial Research Team will be extended for [*] ([*]) days, in order to continue negotiation of the terms and conditions for an extension of the Research Term, if any.
Extension of Research Term. AZ shall have the right to extend the Research Term on an annual basis for up to [ * ]. To exercise such option, AZ shall so notify Array in writing at least three (3) months prior to the expiration of the Research Term (including any extensions thereof in accordance with this Section 2.7) and the Parties shall enter into good faith discussions as to the required number of Array FTEs for such extension of the Research Term. All such Array FTEs shall be funded by AZ at the FTE rate established under Section 6.2.1 below.
Extension of Research Term. Amerimmune may, at its election and after discussing in the JDC, as long as both parties are in mutual agreement, extend the Research Term for up to three (3) one (1) year extension periods (each being a “Research Term Extension”, and each to run consecutively after the end of the then-current Research Term) by giving notice to Amerimmune of each such election at least thirty (30) days prior to the expiration of the then-current Research Term.
Extension of Research Term. With the written agreement of the --------------------------- parties, the Research Term may be extended for up to two (2) years following the Initial Term. If it wishes to extend the Research Term, BMS must notify Pharmacopeia in writing at least six (6) months prior to the then current expiration date for the Research Term. If BMS so notifies Pharmacopeia, the parties shall negotiate in good faith the terms of any such extension.
Extension of Research Term. Celgene may, at its election, extend the Research Term for a two (2) year extension period (to run consecutively after the end of the then-current Research Term) by giving notice to Vividion of such election at least [***] days prior to the expiration of the then-existing Research Term and by paying the Research Term Extension Fee as set forth in Section 6.3.
Extension of Research Term. PFIZER may extend the Research Program in its sole discretion by one year by giving written notice at least 60-days before the end of the initial Research Term.
Extension of Research Term. The Parties may agree to extend the Research Term by mutual consent on such terms and conditions as the Parties may then agree. [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED.
Extension of Research Term. Article 2.3 (Research Term) of the Collaboration Agreement shall be deleted in its entirety and replaced with the following: “The Research term shall commence on the Effective Date and shall expire, on a Program-by-Program basis, upon the earlier of (i) eight (8) years after the Effective Date, or (ii) the date that the last Option with respect to any Collaboration Program is exercised or expires un-exercised by GSK (unless terminated earlier in accordance with this Agreement) (the “Research Term”), subject to extension if mutually agreed in writing by the Parties.”
Extension of Research Term. The Research Term may be extended only by mutual written agreement of the Parties. The Parties acknowledge and agree that, during any extension of the Research Term: (a) the Research Program shall be limited to research and development activities directed to Program Targets for which Incyte retains an unexercised Option, and not (i) any other Program Targets or (ii) the identification of any Targets that are not Program Targets and (b) all costs and expenses of Syros and its Affiliates, including with respect to FTEs (at the Syros FTE Rate) and out-of-pocket costs and expenses, for conducting its activities during such extension shall be funded by Incyte if in excess of the Prepaid Research Amount, in each case ((a) and (b)), unless otherwise mutually agreed by the Parties. For clarity, the Option exercise periods set forth in Section 3.1.1, Section 3.1.2 and Section 3.1.3 shall not be extended by any extension of the Research Term.